#USA #New York #Pomerantz #Sanofi #SNY

Pomerantz Law Firm Takes Action on Behalf of Sanofi Investors

In a significant development for shareholders, Pomerantz LLP has announced it is investigating claims regarding potential securities fraud involving Sanofi, a prominent global pharmaceutical company. The investigation aims to ascertain whether Sanofi and certain executives or directors may have engaged in unlawful business practices that could have misled investors.

Background Information

Sanofi, listed on NASDAQ under the ticker symbol SNY, recently faced substantial scrutiny following the release of mixed results from its Phase 3 clinical trials for itepekimab, a treatment designed to address chronic obstructive pulmonary disease (COPD). On May 30, 2025, the company issued a press release detailing that while the AERIFY-1 trial demonstrated statistically significant and clinically relevant outcomes, the AERIFY-2 trial did not meet its primary endpoint, leading to concerns over the drug's efficacy.

This contradictory data was met with a notable decrease in Sanofi's American Depositary Receipt (ADR) price, which fell by $2.98, or 5.69%, settling at $49.37 after the announcement. The drop sparked immediate reactions from investors and market analysts alike, heightening fears of the potential financial repercussions.

Reasons for the Investigation

Pomerantz LLP suggests that investors who have suffered losses due to this situation may have valid claims based on the handling of the clinical trial data. The firm's inquiry seeks to determine if the behavior of Sanofi and its affiliates fits into the broader category of securities fraud. Potential misconduct could involve misleading statements or omissions regarding the trials or general company performance.

The firm has encouraged affected investors to reach out to legal counsel for a more thorough discussion of their rights and options. Danielle Peyton, a representative from Pomerantz, can be contacted directly for more information or assistance.

About Pomerantz LLP

Established over eight decades ago, Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation. The firm's reputation stems from its dedication to championing the rights of victims of securities fraud and corporate misdeeds. Founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar, the practice has led numerous successful actions to secure financial restitution for aggrieved investors.

This current investigation into Sanofi is part of Pomerantz's ongoing commitment to holding businesses accountable for their actions and safeguarding investors' interests. With a network of offices across major global cities including New York, London, and Paris, the firm aims to cover a wide array of corporate litigation cases and maintain high ethical standards in representing class action claims.

As the investigation unfolds, affected investors are urged to consider joining the class action, as this could lead to a potential recovery of losses related to the performances and actions of Sanofi. The details for joining the class action are provided in the official release from Pomerantz.

Investors looking for justice and accountability are advised to stay informed about the ongoing developments in this case, especially as it may have lasting implications for Sanofi and the broader pharmaceutical industry.

For further inquiries or to discuss participation in the class action, interested parties should reach out to Danielle Peyton at Pomerantz LLP using the provided contact details.